JP2009533465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009533465A5 JP2009533465A5 JP2009505564A JP2009505564A JP2009533465A5 JP 2009533465 A5 JP2009533465 A5 JP 2009533465A5 JP 2009505564 A JP2009505564 A JP 2009505564A JP 2009505564 A JP2009505564 A JP 2009505564A JP 2009533465 A5 JP2009533465 A5 JP 2009533465A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- dvl
- item
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 55
- 229920001184 polypeptide Polymers 0.000 claims description 54
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 54
- 230000003993 interaction Effects 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 102000013814 Wnt Human genes 0.000 claims description 6
- 108050003627 Wnt Proteins 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 101150108602 DVL1 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000004156 Wnt signaling pathway Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79067306P | 2006-04-10 | 2006-04-10 | |
| US60/790,673 | 2006-04-10 | ||
| PCT/US2007/066267 WO2007121147A2 (en) | 2006-04-10 | 2007-04-09 | Disheveled pdz modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009533465A JP2009533465A (ja) | 2009-09-17 |
| JP2009533465A5 true JP2009533465A5 (enExample) | 2010-05-20 |
| JP5290148B2 JP5290148B2 (ja) | 2013-09-18 |
Family
ID=38537937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009505564A Expired - Fee Related JP5290148B2 (ja) | 2006-04-10 | 2007-04-09 | Ｄｉｓｈｅｖｅｌｅｄ（Ｄｖｌ）ＰＤＺ修飾因子 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7695928B2 (enExample) |
| EP (2) | EP2343551B1 (enExample) |
| JP (1) | JP5290148B2 (enExample) |
| CN (2) | CN103351425B (enExample) |
| AU (1) | AU2007238186B2 (enExample) |
| CA (1) | CA2648322C (enExample) |
| ES (2) | ES2385261T3 (enExample) |
| WO (1) | WO2007121147A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI615403B (zh) * | 2007-02-21 | 2018-02-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| KR101278073B1 (ko) * | 2008-08-04 | 2013-06-24 | 연세대학교 산학협력단 | Ｉｄｂｆ의 신규 용도 |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| MX366804B (es) | 2012-02-11 | 2019-07-25 | Genentech Inc | Translocaciones de la r-espondina y sus metodos de uso. |
| GB201220891D0 (en) | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating breast cancers |
| GB201220901D0 (en) | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating pancreatic cancer |
| TWI658049B (zh) | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Ｋｎｔｃ２胜肽及含此胜肽之疫苗 |
| US9520180B1 (en) | 2014-03-11 | 2016-12-13 | Hypres, Inc. | System and method for cryogenic hybrid technology computing and memory |
| GB201421647D0 (en) | 2014-12-05 | 2015-01-21 | Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie | CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8319174D0 (en) * | 1983-07-15 | 1983-08-17 | Erba Farmitalia | Biologically active heptapeptides |
| GB8430255D0 (en) * | 1984-11-30 | 1985-01-09 | Erba Farmitalia | Biologically active oligopeptides |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| CA2345497A1 (en) | 1988-10-28 | 1990-04-28 | Genentech, Inc. | Growth hormone variants and method for forming growth hormone variants |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5688936A (en) * | 1992-06-11 | 1997-11-18 | The Regents Of The University Of California | Vesicle membrane transport proteins |
| JPH08503950A (ja) | 1992-12-02 | 1996-04-30 | アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド | 徐放性成長ホルモン含有マイクロスフェア |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| ES2151079T3 (es) | 1994-09-09 | 2000-12-16 | Takeda Chemical Industries Ltd | Preparacion de liberacion sostenida que contiene una sal metalica de un peptido. |
| WO1996040072A2 (en) | 1995-06-07 | 1996-12-19 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| US6294330B1 (en) | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
| CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| AU5122499A (en) | 1998-07-27 | 2000-02-21 | Genentech Inc. | Improved transformation efficiency in phage display through modification of a coat protein |
| US6610836B1 (en) * | 1999-01-29 | 2003-08-26 | Genome Therapeutics Corporation | Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics |
| WO2002090544A2 (en) | 2001-05-04 | 2002-11-14 | Hybrigenics | Protein-protein interactions in adipocyte cells (3) |
| CA2450236A1 (en) * | 2001-07-06 | 2003-01-16 | Genentech, Inc. | Phage displayed pdz domain ligands |
| US7314974B2 (en) * | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
| US20040247593A1 (en) | 2002-10-04 | 2004-12-09 | Regents Of The University Of California, | Methods for treating cancer by inhibiting Wnt signaling |
| US7795295B2 (en) | 2004-07-01 | 2010-09-14 | The Regents Of The University Of California | Small molecule inhibition of PDZ-domain interaction |
-
2007
- 2007-04-09 WO PCT/US2007/066267 patent/WO2007121147A2/en not_active Ceased
- 2007-04-09 EP EP11154863.2A patent/EP2343551B1/en not_active Not-in-force
- 2007-04-09 JP JP2009505564A patent/JP5290148B2/ja not_active Expired - Fee Related
- 2007-04-09 US US11/733,146 patent/US7695928B2/en not_active Expired - Fee Related
- 2007-04-09 CN CN201310261484.0A patent/CN103351425B/zh not_active Expired - Fee Related
- 2007-04-09 ES ES07760350T patent/ES2385261T3/es active Active
- 2007-04-09 ES ES11154863.2T patent/ES2487637T3/es active Active
- 2007-04-09 EP EP07760350A patent/EP2002259B1/en active Active
- 2007-04-09 CA CA2648322A patent/CA2648322C/en not_active Expired - Fee Related
- 2007-04-09 CN CN2007800216108A patent/CN101467039B/zh not_active Expired - Fee Related
- 2007-04-09 AU AU2007238186A patent/AU2007238186B2/en not_active Ceased
-
2010
- 2010-01-29 US US12/696,875 patent/US7977064B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009533465A5 (enExample) | ||
| Muttenthaler et al. | Solving the α-conotoxin folding problem: efficient selenium-directed on-resin generation of more potent and stable nicotinic acetylcholine receptor antagonists | |
| AU784845B2 (en) | Cell-permeable peptide inhibitors of the JNK signal transduction pathway | |
| Loerch et al. | Unmasking the U2AF homology motif family: a bona fide protein–protein interaction motif in disguise | |
| JP2023107892A (ja) | 安定化ペプチドによって介在される標的タンパク質の分解 | |
| EA200800536A1 (ru) | Тканезащитные пептиды и их применения | |
| Sakurai et al. | Use of a retroinverso p53 peptide as an inhibitor of MDM2 | |
| US20120142613A1 (en) | Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway | |
| Hoshijima et al. | Roles of heterotypic CCN2/CTGF–CCN3/NOV and homotypic CCN2–CCN2 interactions in expression of the differentiated phenotype of chondrocytes | |
| JP2010522541A5 (enExample) | ||
| AU2025204787A1 (en) | COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS | |
| Malkar et al. | Modulation of triple-helical stability and subsequent melanoma cellular responses by single-site substitution of fluoroproline derivatives | |
| JP2010528584A5 (enExample) | ||
| CN116801908A (zh) | 用于降解病毒和宿主蛋白的嵌合缀合物和使用方法 | |
| WO2009112075A1 (en) | Peptides and aptamers thereof as specific modulators of mutant p53 function | |
| CN101583871A (zh) | 基于细胞成像利用hbv衣壳蛋白和表面蛋白的相互作用筛选hbv增殖抑制剂的方法 | |
| Zwanziger et al. | First selective agonist of the neuropeptide Y1‐receptor with reduced size | |
| Altieri et al. | Anti-amyloidogenic property of human gastrokine 1 | |
| CA2357015A1 (en) | Agents for treating human illnesses based on .beta.-catenin, and the production and use thereof | |
| ATE253636T1 (de) | Mit smad wechselwirkende polypeptide und verwendungen davon | |
| Denholt et al. | Identification of novel peptide ligands for the cancer‐specific receptor mutation EFGRvIII using a mixture‐based synthetic combinatorial library | |
| JP2021070652A (ja) | 線維芽細胞増殖因子受容体１結合ペプチド | |
| Roof et al. | Novel peptide ligands of RGS4 from a focused one‐bead, one‐compound library | |
| Bánóczi et al. | Synthesis of cell-penetrating conjugates of calpain activator peptides | |
| DE69925116D1 (de) | Neue, physiologisch aktive peptide und ihre verwendung. |